Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Therapy
New aromatase inhibitors for treatment of metastatic breast cancer examined
November 17th, 2005
Researchers examine new aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma in a recent issue of the journal Cancer. According to a study from Italy, "New aromatase inhibitors (AI) (second-generation: formestane and fadrozole; third-generation: letrozole, anastrozole, vorozole, and exemestane) have been tested in several controlled clinical trials after tamoxifen failure in metastatic breast carcinoma (MBC). They have resulted in better survival compared with megestrol acetate (MEG) in a number of studies." "The authors performed a pooled analysis including all the Phase III trials...
Source: Women's Health Weekly (2005-11-17)
|
